Market cap
$8.5M

InMed Pharmaceuticals Inc. (INM) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. In the last 30 days Quantisnow tracked 13 wire items for INM, including 9 SEC filings, 3 insider trades and 1 M&A update. The most recent was published Nov 10, 2026.

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of orofacial pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies. It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is based in Vancouver, Canada.

Financial highlights

Full financials
Net income, TTM
-$13.16M
Cash
$1.09M

For the twelve months ended Sep 30, 2026, from SEC filings. Not investment advice.

News · 26 weeks39+71%
2026-05-24: 02026-05-31: 12026-06-07: 32026-06-14: 02026-06-21: 02026-06-28: 22026-07-05: 22026-07-12: 22026-07-19: 52026-07-26: 02026-08-02: 02026-08-09: 02026-08-16: 02026-08-23: 02026-08-30: 02026-09-06: 32026-09-13: 22026-09-20: 02026-09-27: 32026-10-04: 22026-10-11: 12026-10-18: 12026-10-25: 32026-11-01: 62026-11-08: 32026-11-15: 0
2026-05-242026-11-15
Mix2490d
  • SEC Filings16(67%)
  • Insider7(29%)
  • M&A1(4%)
Activity · 52 weeks7746 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news

Latest news

25 items

INM FAQ

9 questions
  • What does InMed Pharmaceuticals Inc. do?
    InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of orofacial pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the...
  • What is the latest news on INM?
    In the last 30 days Quantisnow tracked 13 wire items for INM: 9 SEC filings, 3 insider trades and 1 M&A update. The most recent was published on November 10, 2026.
  • Is INM profitable?
    No. InMed Pharmaceuticals Inc. reported a net loss of $13.16M for the twelve months ended Sep 30, 2026.
  • How much cash and debt does INM have?
    InMed Pharmaceuticals Inc. reported $1.09M in cash and cash equivalents on its most recent balance sheet in SEC filings.
  • Where does INM stock trade?
    InMed Pharmaceuticals Inc. (INM) is listed on NASDAQ.
  • What sector and industry is INM in?
    InMed Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.
  • What are analysts saying about INM?
    InMed Pharmaceuticals Inc. has had 1 recent analyst action on file. The most recent action was from HC Wainwright & Co.: Buy with a $6.00 price target on 2021-11-29. Recent price targets cluster around $6.00.
  • What companies are similar to INM?
    Notable peers in the same industry include CRBP (Corbus Pharmaceuticals Holdings Inc.), JAZZ (Jazz Pharmaceuticals plc), TLRY (Tilray Brands Inc.). Compare INM side-by-side with any of them on Quantisnow.
  • How can I track INM on Quantisnow?
    Quantisnow aggregates InMed Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow INM to receive live email and push alerts on every new disclosure.

Is something on this page wrong, or out of date? Request a change